Fisetin

Phase 2Small molecule

MMayo Clinic

Fisetin is one of 185 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

184

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Childhood CancerActive, not recruiting

Carpal Tunnel SyndromeActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

Breast CancerActive, not recruiting

COVID-19Active, not recruiting

OsteoarthritisActive, not recruiting

Common Variable ImmunodeficiencyActive, not recruiting

FunctionNot yet recruiting

GliomaPhase 1

Active, not recruiting

Childhood CancerPhase 2

Active, not recruiting

Carpal Tunnel SyndromePhase 2

Active, not recruiting

Interstitial Lung DiseasePhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

OsteoarthritisPhase 2/Phase 3

Active, not recruiting

Common Variable ImmunodeficiencyPhase 2

Active, not recruiting

FunctionPhase 2

Not yet recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Fisetin

MMayo Clinic

Phase 2

2 2

Lexiscan

Astellas

Preclinical

1 3

Chirocaine

PPurdue Pharma LP

Preclinical

1 4

Vfend

PPrism Pharmaceuticals

Preclinical

—5

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 6

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 7

Lipegfilgrastim

Merck & Co.

Preclinical

1 8

Promestriene

UUniversity of Sao Paulo General Hospital

Preclinical

1 9

Citalopram Hydrobromide

TTorrent Pharmaceuticals Limited

Preclinical

1 10

Escitalopram Oxalate

TTorrent Pharmaceuticals Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Inflammation

NCT04476953

Q4 2026

Phase 2Active, not recruiting

Common Variable Immunodeficiency

NCT05593588

Q2 2027

Phase 2Recruiting

Mobility Impairment

NCT06399809

Q3 2027

Phase 2Recruiting

Function

NCT07676435

Phase 1Recruiting

Glioma

NCT07025226

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06113016·164 enrolled

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT05595499·88 enrolled

Osteoarthritis2 trials

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

Active, not recruiting·SSteadman Philippon Research Institute·Phase 1/2·NCT04815902·100 enrolled

GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression

Withdrawn·—·Phase 2/3·NCT05482672

Inflammation1 trial

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

Active, not recruiting·MMayo Clinic·Phase 2·NCT04476953·80 enrolled

Carpal Tunnel Syndrome1 trial

A Study of Fisetin to Treat Carpal Tunnel Syndrome

Completed·—·Phase 2·NCT05416515·40 enrolled

COVID-191 trial

COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes

Terminated·MMayo Clinic·Phase 2·NCT04537299·20 enrolled

10 more indications

Childhood Cancer1 trial

An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT04733534·110 enrolled

ART1 trial

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

Active, not recruiting·SSteadman Philippon Research Institute·Phase 1/2·NCT05025956·68 enrolled

Complication1 trial

COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

Completed·—·Phase 2·NCT04771611·55 enrolled

Recovery1 trial

Enhancing Recovery Through a Combined Mechanobiologic Intervention Following Meniscus Repair

Withdrawn·AAustin V Stone·Phase 2/3·NCT05505747

Mobility Impairment1 trial

Fisetin to Reduce Senescence and Mobility Impairment in PAD

Recruiting·NNorthwestern University·Phase 2·NCT06399809·34 enrolled

Older Patients1 trial

Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity

Not yet recruiting·OOve Andersen·Phase 1/2·NCT06431932·60 enrolled

Humans1 trial

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

Completed·—·Phase 2·NCT04313634·74 enrolled

Glioma1 trial

MC230715 Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies

Recruiting·MMayo Clinic·Phase 1·NCT07025226·30 enrolled

Function1 trial

A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE ONGOING LUNG DECLINE WITH AGE INTENSIFIED RESPONSE (OLD AIR)

Recruiting·CCedars-Sinai Medical Center·Phase 2·NCT07676435·40 enrolled

Common Variable Immunodeficiency1 trial

Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)

Active, not recruiting·AAvni Joshi·Phase 2·NCT05593588·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Fisetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fisetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fisetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMayo Clinic

Fisetin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Breast Cancer2 trials

Osteoarthritis2 trials

Inflammation1 trial

Carpal Tunnel Syndrome1 trial

COVID-191 trial

Childhood Cancer1 trial

ART1 trial

Complication1 trial

Recovery1 trial

Mobility Impairment1 trial

Older Patients1 trial

Humans1 trial

Glioma1 trial

Function1 trial

Common Variable Immunodeficiency1 trial

References

Drug Info

Quick Facts

Related News